Topotarget, the Copenhagen, Denmark-based biotech specialising in cancer therapies, has announced the establishment of a global oncology advisory board to assist in the development of the company’s lead compound, belinostat. The leading oncologists appointed to the board are Matti Aapro of the Multidisciplinary Oncology Institute, Genolier, Switzerland; James Cassidy of the University of Glasgow, Scotland; Alain Catalin Mita of the University of Texas Health Science Center San Antonio, Texas US; Hans-Joachim Schmoll of the Martin Luther University, Halle-Wittenberg, Germany; and Daniel D. Von Hoff of the Translational Genomics Research Institute, Phoenix, Arizona, US. Jean-Louis Misset of the University Paris VII is chairing the board.
Copyright 2011 Evernow Publishing Ltd